DS, which develops in approximately 5–25% of patients, is a severe life-threatening condition triggered by the release of inflammatory cytokines, such as tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β) and chemokines like monocyte chemoattractant protein-1 (MCP-1) (CCL2) [24]. This evidence concerns the gene CCL2 and Dravet syndrome.